Two-dimensional gel electrophoresis revealed antipsychotic drugs induced protein expression modulations in C6 glioma cells

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 1-11

  Chen, Mao Liang ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Antipsychotic drugs; ARHGDIA; GFAP; Glia; Proteome

Indexed keywords

ANIONIC TRYPSIN 1; CLOZAPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HALOPERIDOL; MEMBRANE PROTEIN; NERVE CELL ADHESION MOLECULE; PARVALBUMIN; PERICENTRIN; PEROXIREDOXIN 1; RH GDP DISSOCIATION INHIBITOR 1; RISPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLIOMA CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CLOZAPINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FRONTAL LOBE; GENE EXPRESSION; GLIOMA; HALOPERIDOL; RATS; RISPERIDONE; TIME FACTORS;

EID: 84867786641     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.08.013     Document Type: Article

References (48)

1. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., et al. Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder. Biol Psychiatry 2008, 63:678-685.
2. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., et al. Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:967-976.
3. Bao A.M., Ruhe H.G., Gao S.F., Swaab D.F. Neurotransmitters and neuropeptides in depression. Handbook of clinical neurology 2012, 106:107-136. P.J. Vinken, G.W. Bruyn (Eds.).
4. Barresi M.J., Burton S., Dipietrantonio K., Amsterdam A., Hopkins N., Karlstrom R.O. Essential genes for astroglial development and axon pathfinding during zebrafish embryogenesis. Dev Dyn 2010, 239:2603-2618.
5. Bartzokis G. Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Front Biosci 2012, 17:2695-2733.
6. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res 2009, 113:322-331.
7. Blindt R., Bosserhoff A.K., Dammers J., Krott N., Demircan L., Hoffmann R., et al. Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. Cardiovasc Res 2004, 62:212-222.
8. Boureux A., Vignal E., Faure S., Fort P. Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol 2007, 24:203-216.
9. Bruses J.L. N-cadherin regulates primary motor axon growth and branching during zebrafish embryonic development. J Comp Neurol 2011, 519:1797-1815.
10. Bullock W.M., Cardon K., Bustillo J., Roberts R.C., Perrone-Bizzozero N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry 2008, 165:1594-1603.
11. Bustelo X.R., Sauzeau V., Berenjeno I.M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007, 29:356-370.
12. Callister S.J., Barry R.C., Adkins J.N., Johnson E.T., Qian W.J., Webb-Robertson B.J., et al. Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 2006, 5:277-286.
13. Cates M.S., Berry M.B., Ho E.L., Li Q., Potter J.D., Phillips G.N. Metal-ion affinity and specificity in EF-hand proteins: coordination geometry and domain plasticity in parvalbumin. Structure 1999, 7:1269-1278.
14. Cates M.S., Teodoro M.L., Phillips G.N. Molecular mechanisms of calcium and magnesium binding to parvalbumin. Biophys J 2002, 82:1133-1146.
15. Chen S.Y., Huang P.H., Cheng H.J. Disrupted-in-schizophrenia 1-mediated axon guidance involves TRIO-RAC-PAK small GTPase pathway signaling. Proc Natl Acad Sci U S A 2011, 108:5861-5866.
16. Danovich L., Veenman L., Leschiner S., Lahav M., Shuster V., Weizman A., et al. The influence of clozapine treatment and other antipsychotics on the 18kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 2008, 18:24-33.
17. Delaval B., Doxsey S.J. Pericentrin in cellular function and disease. J Cell Biol 2010, 188:181-190.
18. Fayed N., Modrego P.J., Rojas-Salinas G., Aguilar K. Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen 2011, 26:450-456.
19. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 2003, 8:811-820.
20. Gianfrancesco F., Pesa J., Wang R.H., Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm 2006, 63:431-441.
21. Han D.K., Eng J., Zhou H., Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 2001, 19:946-951.
22. Hattori T., Shimizu S., Koyama Y., Yamada K., Kuwahara R., Kumamoto N., et al. DISC1 regulates cell-cell adhesion, cell-matrix adhesion and neurite outgrowth. Mol Psychiatry 2010, 15(778):98-809.
23. Herskowitz J.H., Seyfried N.T., Duong D.M., Xia Q., Rees H.D., Gearing M., et al. Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J Proteome Res 2010, 9:6368-6379.
24. Hill J.J., Hashimoto T., Lewis D.A. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2006, 11:557-566.
25. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996, 153:151-162.
26. Ide M., Lewis D.A. Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol Psychiatry 2010, 68:25-32.
27. Jimenez-Rivera C.A., Figueroa J., Vazquez-Torres R., Velez-Hernandez M.E., Schwarz D., Velasquez-Martinez M.C., et al. Presynaptic inhibition of glutamate transmission by alpha2 receptors in the VTA. Eur J Neurosci 2012, 35:1406-1415.
28. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999, 156:885-890.
29. Kornhuber J., Wiltfang J., Riederer P., Bleich S. Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution. Eur Arch Psychiatry Clin Neurosci 2006, 256:274-280.
30. Lee Y.M., Park S.H., Shin D.I., Hwang J.Y., Park B., Park Y.J., et al. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J Biol Chem 2008, 283:9986-9998.
31. Martins-de-Souza D., Gattaz W.F., Schmitt A., Novello J.C., Marangoni S., Turck C.W., et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 9:17.
32. Nardin P., Tramontina A.C., Quincozes-Santos A., Tortorelli L.S., Lunardi P., Klein P.R., et al. In vitro S100B secretion is reduced by apomorphine: effects of antipsychotics and antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1291-1296.
33. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
34. Numata S., Iga J., Nakataki M., Tayoshi S., Tanahashi T., Itakura M., et al. Positive association of the pericentrin (PCNT) gene with major depressive disorder in the Japanese population. J Psychiatry Neurosci 2009, 34:195-198.
35. Peleg-Raibstein D., Knuesel I., Feldon J. Amphetamine sensitization in rats as an animal model of schizophrenia. Behav Brain Res 2008, 191:190-201.
36. Pennington K., Dicker P., Hudson L., Cotter D.R. Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders. Schizophr Res 2008, 106:164-171.
37. Pennington K., Focking M., McManus C.A., Pariante C.M., Dunn M.J., Cotter D.R. A proteomic investigation of similarities between conventional and herbal antidepressant treatments. J Psychopharmacol 2009, 23:520-530.
38. Pihan G.A., Purohit A., Wallace J., Knecht H., Woda B., Quesenberry P., et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998, 58:3974-3985.
39. Pisitkun T., Bieniek J., Tchapyjnikov D., Wang G., Wu W.W., Shen R.F., et al. High-throughput identification of IMCD proteins using LC-MS/MS. Physiol Genomics 2006, 25:263-276.
40. Pujana M.A., Han J.D., Starita L.M., Stevens K.N., Tewari M., Ahn J.S., et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007, 39:1338-1349.
41. Quincozes-Santos A., Bobermin L.D., Kleinkauf-Rocha J., Souza D.O., Riesgo R., Goncalves C.A., et al. Atypical neuroleptic risperidone modulates glial functions in C6 astroglial cells. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:11-15.
42. Rasin M.R., Gazula V.R., Breunig J.J., Kwan K.Y., Johnson M.B., Liu-Chen S., et al. Numb and Numbl are required for maintenance of cadherin-based adhesion and polarity of neural progenitors. Nat Neurosci 2007, 10:819-827.
43. Rieder C.L., Faruki S., Khodjakov A. The centrosome in vertebrates: more than a microtubule-organizing center. Trends Cell Biol 2001, 11:413-419.
44. Rothermundt M., Falkai P., Ponath G., Abel S., Burkle H., Diedrich M., et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004, 9:897-899.
45. Shimmura C., Suda S., Tsuchiya K.J., Hashimoto K., Ohno K., Matsuzaki H., et al. Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS One 2011, 6:e25340.
46. Steffek A.E., McCullumsmith R.E., Haroutunian V., Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 2008, 103:71-82.
47. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., Okada M. Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012, 165:1543-1555.
48. Toro C.T., Hallak J.E., Dunham J.S., Deakin J.F. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 2006, 404:276-281.